Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Nivolumab Combined With Daratumumab With or Without Low-dose Cyclophosphamide in Relapsed/Refractory Multiple Myeloma

NCT03184194 is registered in ClinicalTrials.gov with Amsterdam UMC, location VUmc as lead sponsor.

NCT NCT03184194
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03184194 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Nivolumab Combined With Daratumumab With or Without Low-dose Cyclophosphamide in Relapsed/Refractory Multiple Myeloma
Lead sponsor
Amsterdam UMC, location VUmc
Phase
Phase 2
Overall status
Completed
Start date
February 21, 2018
Completion date
January 25, 2024
Enrollment
62 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

myeloma